← Leaderboards
Julie Gunnells Ledford
Duke University
$8,824,020
Attributed
$12,348,619
Total exposure
9
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2008–25$2.5M$1.9M$1.3M$625K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,348,619 · 9
By mechanism
R01$7,004,137 · 3
R42$3,433,831 · 1
R21$844,250 · 2
R00$715,959 · 1
K99$201,408 · 1
F32$149,034 · 1
Top collaborators
- Scott Boitano4 shared
- Monica Kraft2 shared
- Heidi M. Mansour2 shared
- Josef Vagner2 shared
Most similar at Duke University
Same institution · by research overlap
- Joseph Heitman$44,576,851
- Rima F Kaddurah-Daouk$56,438,861
- Kenneth D Poss$25,540,868
- Donald P McDonnell$25,108,849
- Ann Marie Pendergast$20,201,860
Others in their field
Top investigators on “Asthma”
- James E. Gern · University Of Wisconsin-Madison$159,588,264
- William W. Busse · University Of Wisconsin Madison$104,093,792
- Scott T Weiss · University Of California, San Diego$98,211,117
- David T Mauger · Pennsylvania State Univ Hershey Med Ctr$79,309,576
- Fernando D Martinez · University Of Arizona$66,357,737
- Wanda Phipatanakul · Boston Children'S Hospital$50,505,446
Research focus
AsthmaLungResponsePlayInflammationAsthmaticCellsEpithelial CellsInflammatoryProteinsLeadLinkAirway HyperresponsivenessUnited StatesAirway InflammationInfectionChildMediatingPulmonary Surfactant-Associated Protein AMycoplasma PneumoniaeHost DefenseProductionSerumAttenuated
Grant awards (28)
A role for pharmaceutical control of protease-activated receptor-2 for the treatment of asthma$759,637
R01 · FY2025 · AI
Defining mechanisms of CC16 on epithelial-driven host responses to pathogens$601,809
R01 · FY2025 · HL · contact PI
A role for pharmaceutical control of protease-activated receptor-2 for the treatment of asthma$716,690
R01 · FY2024 · AI
Defining mechanisms of CC16 on epithelial-driven host responses to pathogens$606,414
R01 · FY2024 · HL · contact PI
Determining the Role of Creatine Kinase in Asthma$191,875
R21 · FY2024 · AI · contact PI
Development of SP-A Derived Peptidomimetics for the Treatment of Asthma - Phase II$1,478,237
R42 · FY2023 · HL · contact PI
CC16: A Link between Airway Infection and Obstructive Lung Disease$438,356
R01 · FY2023 · HL · contact PI
Determining the Role of Creatine Kinase in Asthma$230,250
R21 · FY2023 · AI · contact PI
Development of SP-A Derived Peptidomimetics for the Treatment of Asthma - Phase II$1,955,594
R42 · FY2022 · HL · contact PI
CC16: A Link between Airway Infection and Obstructive Lung Disease$445,265
R01 · FY2022 · HL · contact PI
CC16: A Link between Airway Infection and Obstructive Lung Disease$516,062
R01 · FY2021 · HL · contact PI
CC16: A Link between Airway Infection and Obstructive Lung Disease$502,989
R01 · FY2020 · HL · contact PI
CC16: A Link between Airway Infection and Obstructive Lung Disease$516,438
R01 · FY2019 · HL · contact PI
Surfactant Protein-A regulation of eosinophil apoptosis in asthma$380,339
R01 · FY2019 · HL · contact PI
Surfactant Protein A as a Novel Therapeutic for Asthma$230,250
R21 · FY2019 · AI · contact PI
Surfactant Protein-A regulation of eosinophil apoptosis in asthma$380,339
R01 · FY2018 · HL · contact PI
Surfactant Protein A as a Novel Therapeutic for Asthma$191,875
R21 · FY2018 · AI · contact PI
Surfactant Protein-A regulation of eosinophil apoptosis in asthma$380,339
R01 · FY2017 · HL · contact PI
Surfactant Protein-A regulation of eosinophil apoptosis in asthma$380,339
R01 · FY2016 · HL · contact PI
The role of SP-A in Mp-induced exacerbations during allergic airway disease.$232,675
R00 · FY2016 · HL · contact PI
Surfactant Protein-A regulation of eosinophil apoptosis in asthma$379,121
R01 · FY2015 · HL · contact PI
The role of SP-A in Mp-induced exacerbations during allergic airway disease.$234,284
R00 · FY2015 · HL · contact PI
The role of SP-A in Mp-induced exacerbations during allergic airway disease.$249,000
R00 · FY2014 · HL · contact PI
The role of SP-A in Mp-induced exacerbations during allergic airway disease.$100,704
K99 · FY2013 · HL · contact PI
The role of SP-A in Mp-induced exacerbations during allergic airway disease.$100,704
K99 · FY2012 · HL · contact PI
Role of Surfactant in Mycoplasma Pulmonary Infection and Exacerbation$52,154
F32 · FY2010 · HL · contact PI
Role of Surfactant in Mycoplasma Pulmonary Infection and Exacerbation$50,054
F32 · FY2009 · HL · contact PI
Role of Surfactant in Mycoplasma Pulmonary Infection and Exacerbation$46,826
F32 · FY2008 · HL · contact PI